Skip to main content
    I

    Immunovant Inc (IMVT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $33.21
    -0.07 (-0.21%)

    Market Cap: $6.89B

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Immunovant Inc (IMVT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Immunovant (IMVT) has a market cap of $6.89B and an enterprise value of $6.16B. It kept -7173.52% of revenue as net income over the last 12 months. Revenue grew 4334.38% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 10.49% below the market cap, as cash exceeds debt.

    Market Cap$6.89B
    Enterprise Value$6.16B
    Latest price (Nov 17, 2026)$33.21

    Key Dates

    The next earnings report is expected on Feb 4, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 4, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndMarch

    Share Statistics

    The share count rose 0.55% in the quarter ended Sep 30, 2026 and grew 18.79% a year over 2 years.

    Shares Outstanding206.67M
    Shares Change (YoY)+19.02%
    Shares Change (QoQ)+0.55%
    Share Count Growth (2Y CAGR)+18.79%

    Price Statistics

    The stock is up 39.89% over 52 weeks and trades 2.53% above its 50-day average.

    Beta (1Y)1.54
    52-Week Change+39.89%
    1-Month Change+20.24%
    3-Month Change-26.13%
    6-Month Change+26.32%
    5-Year Change+262.81%
    Total Return (1Y)+39.89%
    Total Return (3Y CAGR)-0.60%
    Total Return (5Y CAGR)+33.29%
    Return vs SPY (1Y)+28.63%
    Max Drawdown (1Y)-40.55%
    Max Drawdown (3Y)-69.88%
    Sharpe Ratio (1Y)0.62
    Correlation with SPY (1Y)0.39
    50-Day Average$32.39
    200-Day Average$32.42
    52-Week Range$21.86 to $45.42
    RSI (14 Days)54.3
    Average Volume (20 Days)1.41M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.31x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio7.31x
    Quick Ratio7.31x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -77.47% over the last 12 months, against a 5-year average of -50.27%.

    Return on Equity (ROE)-77.47%
    Return on Assets (ROA)-66.88%
    Return on Capital Employed (ROCE)-77.67%
    ROE (5Y Average)-50.27%
    ROA (5Y Average)-45.49%
    ROIC (5Y Average)-49.47%
    Asset Turnover0.01x

    Scores

    IMVT has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $7.09M over the last 12 months.

    Revenue$7.09M
    Revenue Growth (YoY)+4334.38%
    Operating Income-$531.30M
    Pretax Income-$510.25M
    Net Income-$508.96M
    EBITDA-$509.88M
    EBIT-$510.25M
    Reported EPS (TTM)-$2.43

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 86.33% of the $760.97M in total assets.

    Cash and Equivalents$722.27M
    Total Debt$0
    Net Cash$722.27M
    Net Cash Per Share$3.49
    Working Capital$656.02M
    Shareholder Equity$656.95M
    Book Value Per Share$3.18
    Total Assets$760.97M
    Total Liabilities$104.02M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $8.00K of capital spending, operating cash flow left -$395.01M of free cash flow.

    Operating Cash Flow-$395.00M
    Capital Expenditures$8.00K
    Free Cash Flow-$395.01M
    FCF Per Share-$1.91
    Depreciation and Amortization$378.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -7488.36%.

    Operating Margin-7488.36%
    Pretax Margin-7191.73%
    Net Margin-7173.52%
    EBITDA Margin-7186.40%
    EBIT Margin-7191.73%
    FCF Margin-5567.47%

    Growth

    Book Value Per Share Growth (2Y CAGR)-0.76%
    Tangible Book Per Share Growth (2Y CAGR)-0.76%

    Revenue and profit by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About IMVT

    What is IMVT's market cap?

    Immunovant has a market cap of $6.89B. Its enterprise value, which adds debt and subtracts cash, is $6.16B.

    How many shares of IMVT are outstanding?

    Immunovant has 206.67M shares outstanding. The count is up 19.02% from a year earlier.

    Does IMVT pay a dividend?

    No. Immunovant does not pay a dividend.

    How much debt does IMVT have?

    Immunovant has $0 of total debt and $722.27M of cash and equivalents, a net cash position of $722.27M.